Atea Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Atea PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 4.8% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 119.2% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -65.4% betragen.

Wichtige Informationen

-4.8%

Wachstumsrate der Gewinne

13.1%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	119.2%
Zukünftige Eigenkapitalrendite	-65.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	16 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Jan 05

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Nov 25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Oct 20

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Jun 17

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 15

Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

May 13

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Apr 08

Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Mar 06

Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Jan 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:AVIR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	32	-211	-192	-166	2
12/31/2025	8	-181	-204	-178	3
12/31/2024	N/A	-192	-108	-81	2
6/30/2024	N/A	-176	-121	-121	N/A
3/31/2024	N/A	-164	-95	-95	N/A
12/31/2023	N/A	-136	-85	-85	N/A
9/30/2023	N/A	-131	-85	-85	N/A
6/30/2023	N/A	-106	-89	-89	N/A
3/31/2023	N/A	-109	-94	-92	N/A
12/31/2022	N/A	-116	-123	-121	N/A
9/30/2022	192	36	-177	-175	N/A
6/30/2022	225	16	-133	-131	N/A
3/31/2022	285	48	-129	-129	N/A
12/31/2021	351	121	-87	-87	N/A
9/30/2021	208	25	307	307	N/A
6/30/2021	175	35	275	275	N/A
3/31/2021	115	24	284	284	N/A
12/31/2020	49	-11	297	297	N/A
9/30/2020	N/A	-36	-26	-26	N/A
6/30/2020	N/A	-22	-20	-20	N/A
3/31/2020	N/A	-16	-14	-14	N/A
12/31/2019	N/A	-14	-13	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AVIR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: AVIR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: AVIR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: AVIRDie Einnahmen des Unternehmens (119.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: AVIRDie Einnahmen des Unternehmens (119.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AVIR wird voraussichtlich in 3 Jahren unrentabel sein.

Atea Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 18% to US$5.50

Price target decreased by 15% to US$5.33

Price target decreased to US$9.00

Consensus forecasts updated

Price target decreased to US$10.50

Price target decreased to US$11.67

Recent updates

Founder notifies of intention to sell stock

Atea Pharmaceuticals Provides Update on Global Phase 3 Rise-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Independent Director recently sold US$61k worth of stock

Price target increased by 18% to US$5.50

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2024

Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Founder notifies of intention to sell stock

Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19

Price target decreased by 15% to US$5.33

Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023

Atea Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Insufficient new directors

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Defensive Index

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR).

Concentra Biosciences, LLC submitted a non-binding proposal to acquire 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR) for approximately $480 million.

Investor sentiment deteriorates as stock falls 16%

Price target decreased to US$9.00

Atea Pharmaceuticals, Inc. Provides an Update on the Clinical Development Programs for 2023

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Lead Independent Director notifies of intention to sell stock

Lead Independent Director recently sold US$215k worth of stock

Third quarter 2022 earnings released: US$0.097 loss per share (vs US$0.34 loss in 3Q 2021)

Atea Pharmaceuticals, Inc. Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Atea wins FDA Fast Track status for dengue treatment

Investor sentiment deteriorated over the past week

Atea Pharmaceuticals, Inc. to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Consensus forecasts updated

First half 2022 earnings released

Atea Pharmaceuticals Q2 2022 Earnings Preview

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Growth Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$10.50

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$11.67

Atea Pharmaceuticals, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

Price target decreased to US$15.50

Consensus EPS estimates increase by 131%

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Independent Director recently bought US$103k worth of stock

Consensus forecasts updated

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in Covid-19

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Investor sentiment deteriorated over the past week

Price target decreased to US$16.25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

Consensus EPS estimates increase to US$0.62

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals, Inc. Announces Positive Interim Results from the Global Phase 2 Study Evaluating AT-527

Independent Director Andrew A. Hack has left the company

Independent Director Andrew A. Hack has left the company

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$1.70b

Investor sentiment improved over the past week